Nutrix’s tSense Honored with CES Innovation Award® 2026 in Digital Health Nutrix AG is proud to announce that tSense, our non-invasive testosterone monitoring sensor, has been recognized as a CES Innovation Award® 2026 honoree in the Digital Health category at CES 2026.

The CES Innovation Awards® program one of the world’s most prestigious recognitions for consumer technology, celebrates exceptional engineering and design across emerging tech products. This year’s program saw a record-breaking number of submissions from innovators

tSense is the world’s first Swiss-made, non-invasive saliva sensor that enables real-time testosterone monitoring at home. Using breakthrough sensing chemistry with multiple patents pending, the device delivers medical-grade results in just three minutes and pairs seamlessly with Nutrix’s gSense AI health platform for tracking, analysis, and personalized insights.

By eliminating the need for invasive blood draws or delayed laboratory kits, tSense removes barriers to frequent hormone monitoring — a capability with wide applications across men’s hormonal health, perimenopause and menopause care, sports performance, therapy management, and preventive wellness.

This honor follows Nutrix’s earlier recognition at CES 2025, where cortiSense — our non-invasive cortisol sensor — also received a CES Innovation Award for its transformative approach to stress and burnout monitoring.

tSense will be showcased at CES 2026 in Las Vegas alongside Nutrix’s Hormonal Intelligence platform. Visitors can experience live demonstrations of how Nutrix is expanding accessible at-home hormone monitoring and shaping the future of preventive health.

For more information and press inquiries about tSense or Nutrix’s presence at CES, please contact us.